News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NuVasive, Inc. (NUVA) Reports Third Quarter 2012 Financial Results



10/24/2012 8:57:25 AM

SAN DIEGO, CA--(Marketwire - October 24, 2012) - NuVasive, Inc. (NASDAQ: NUVA)

  • Third quarter 2012 total revenue of $148.4 million; up 11.7% from third quarter 2011
  • GAAP net income of $2.4 million, or $0.05 per share
  • Non-GAAP net income of $10.1 million, or $0.23 per share

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today financial results for the quarter ended September 30, 2012.

Alex Lukianov, Chairman and Chief Executive Officer, said, "Market challenges led third quarter results to fall short of our expectations. We provided early warning of the shortfall and have implemented a plan to address the issues. We are re-engaging with our sales force on a deeper level, accelerating the pace of sales force hiring to more than compensate for losses in the quarter, and increasing executive engagement with our top customers. Our market share taking strategy continues to be intact and we have a number of growth catalysts that will help drive growth for the balance of this year and beyond. We are in a unique position as the spine market continues to shift toward minimally invasive solutions and we intend to fully capitalize upon it."

NuVasive reported third quarter 2012 revenue of $148.4 million, an 11.7% increase over the $132.9 million for the third quarter 2011 and 3.9% decrease compared to the $154.4 million reported for the second quarter 2012.

Gross profit for the third quarter 2012 was $110.6 million and gross margin was 74.6%, compared to a gross profit of $106.9 million and a gross margin of 80.4% for the third quarter 2011. For the second quarter 2012, gross profit was $117.9 million and gross margin was 76.3%.

Total operating expenses for the third quarter 2012 were $98.1 million compared to $198.3 million in the third quarter 2011 and $104.9 million in the second quarter 2012. The lower operating expenses in the third quarter 2012 compared to the prior year were primarily attributable to a $101.2 million charge related to a litigation liability in the prior year.

On a GAAP basis, the Company reported net income of $2.4 million, or $0.05 per share, for the third quarter 2012.

On a Non-GAAP basis, the Company reported net income of $10.1 million, or $0.23 per share, for the third quarter 2012. The Non-GAAP earnings per share calculations for the third quarter exclude, (i) non-cash stock-based compensation of $5.4 million; (ii) certain intellectual property litigation expenses of $751 thousand; (iii) amortization of intangible assets of $3.1 million; (iv) acquisition related items of $387 thousand; and (v) non-cash interest expense on convertible notes of $3.2 million.

Cash, cash equivalents and short and long-term marketable securities were $285.0 million at September 30, 2012.

Updated 2012 Full Year Financial Guidance

  • Revenue of approximately $601 - $606 million; compared to approximately $625 million previously
  • GAAP EPS of approximately $0.11 to $0.13; compared to approximately $0.16 previously
  • Non-GAAP EPS of approximately $0.88 to $0.90; compared to approximately $0.97 previously
  • Non-GAAP Operating Margin of approximately 14.0%; compared to approximately 14.5% previously
  • GAAP effective tax rate of approximately 60%; compared to approximately 55% previously
  • Non-GAAP effective tax rate of approximately 40% remains unchanged

2012 Reconciliation of Full Year EPS Guidance Revised Guidance (2) Prior ------------------------- Guidance (1) Low High ------------ ------------ ------------ GAAP earnings per share guidance $ 0.16 $ 0.11 $ 0.13 Non-cash stock based compensation 0.43 0.37 0.37 Certain intellectual property litigation expenses 0.03 0.04 0.04 Amortization of intangible assets 0.16 0.16 0.16 Acquisition related items (3) 0.02 0.03 0.03 Non-cash interest expense on convertible notes 0.17 0.17 0.17 ------------ ------------ ------------ Non-GAAP earnings per share guidance $ 0.97 $ 0.88 $ 0.90 ============ ============ ============ Weighted shares outstanding - basic (4) 43,500 43,500 43,500 ============ ============ ============ Weighted shares outstanding - diluted (4) 45,000 44,500 44,500 ============ ============ ============ (1) Effective tax rate of ~55% applied to GAAP earnings and ~40% applied to Non-GAAP adjustments (2) Effective tax rate of ~60% applied to GAAP earnings and ~40% applied to Non-GAAP adjustments (3) Acquisition related items include expenses associated with prior M&A activity and as incurred (4) Weighted shares outstanding shown as pre "if-converted" method 2012 Guidance Reconciliation of Non-GAAP Operating Margin % Prior Revised Guidance Guidance ---------- ---------- Gross Margin % [A] ~75.5% ~75.0% Non-GAAP Operating Expenses [B] ~61.0% ~61.0% Non-cash stock-based compensation ~5.0% ~4.5% Certain intellectual property litigation expenses ~0.5% ~0.5% Amortization of intangible assets ~2.0% ~2.0% Acquisition related items* ~0.2% ~0.3% ---------- ---------- GAAP Operating Expenses ~68.7% ~68.3% ---------- ---------- Non-GAAP Operating Margin % [A-B] ~14.5% ~14.0% ---------- ---------- * Acquisition related items include expenses associated with prior M&A activity and as incurred

Reconciliation of Non-GAAP Information
Management uses certain Non-GAAP financial measures such as Non-GAAP operating margin and Non-GAAP earnings per share, which exclude such items as non-cash stock-based compensation, certain intellectual property litigation expenses, amortization of intangible assets, acquisition related items, and non-cash interest expense on convertible notes. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the Non-GAAP financial measures provided in this earnings release excluding these costs and uses these Non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these Non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These Non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from Non-GAAP measures used by other companies. Set forth below are reconciliations of the Non-GAAP financial measures to the comparable GAAP financial measure.

Reconciliation of Third Quarter 2012 Results Pre-Tax Earnings (in thousands, except per share data) Adjustments Net of Tax Per Share ----------- ----------- ----------- GAAP net income $ 2,354 $ 0.05 Non-cash stock-based compensation $ 5,434 3,260 0.07 Certain intellectual property litigation expenses 751 451 0.01 Amortization of intangible assets 3,081 1,849 0.04 Acquisition related items 387 232 0.01 Non-cash interest expense on convertible notes 3,202 1,921 0.04 ----------- ----------- Non-GAAP earnings $ 10,067 $ 0.23 =========== =========== Weighted shares outstanding - diluted 44,735 =========== Reconciliation of Year To Date 2012 Results Pre-Tax Earnings (in thousands, except per share data) Adjustments Net of Tax Per Share ----------- ----------- ----------- GAAP net income $ 5,890 $ 0.13 Non-cash stock-based compensation $ 20,400 12,240 0.28 Certain intellectual property litigation expenses 1,567 940 0.02 Amortization of intangible assets 8,830 5,298 0.12 Acquisition related items 1,420 852 0.02 Non-cash interest expense on convertible notes 9,435 5,661 0.13 ----------- ----------- Non-GAAP earnings $ 30,881 $ 0.70 =========== =========== Weighted shares outstanding - diluted 44,151 ===========

Conference Call
NuVasive will hold a conference call today at 8:00 a.m. ET / 5:00 a.m. PT to discuss the results. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com.

After the live webcast, the call will remain available on NuVasive's website, www.nuvasive.com, through November 23, 2012. In addition, a telephonic replay of the call will be available until November 7, 2012. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use pin number 399418.

About NuVasive
NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $7.9 billion global spine market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 75 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

NuVasive, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, -------------------- -------------------- 2012 2011 2012 2011 --------- --------- --------- --------- Revenue $ 148,391 $ 132,880 $ 454,501 $ 390,312 Cost of goods sold (excluding amortization of purchased technology) 37,746 26,015 111,213 75,049 --------- --------- --------- --------- Gross profit 110,645 106,865 343,288 315,263 Operating expenses: Sales, marketing and administrative 87,052 85,482 273,669 254,025 Research and development 7,933 10,092 27,932 31,119 Amortization of intangible assets 3,081 1,504 8,830 4,241 Litigation award - 101,200 - 101,200 --------- --------- --------- --------- Total operating expenses 98,066 198,278 310,431 390,585 Interest and other expense, net: Interest income 249 257 661 591 Interest expense (6,885) (7,276) (20,682) (10,962) Other income, net 260 1,726 146 2,303 --------- --------- --------- --------- Total interest and other expense, net (6,376) (5,293) (19,875) (8,068) --------- --------- --------- --------- Income (loss) before income taxes 6,203 (96,706) 12,982 (83,390) Income tax expense (benefit) 4,064 (29,031) 7,764 (22,715) --------- --------- --------- --------- Consolidated net income (loss) $ 2,139 $ (67,675) $ 5,218 $ (60,675) ========= ========= ========= ========= Net loss attributable to noncontrolling interests $ (215) $ (123) $ (672) $ (862) ========= ========= ========= ========= Net income (loss) attributable to NuVasive, Inc. $ 2,354 $ (67,552) $ 5,890 $ (59,813) ========= ========= ========= ========= Net income (loss) per share attributable to NuVasive, Inc.: Basic $ 0.05 $ (1.69) $ 0.14 $ (1.50) ========= ========= ========= ========= Diluted $ 0.05 $ (1.69) $ 0.13 $ (1.50) ========= ========= ========= ========= Weighted average shares outstanding: Basic 43,488 39,892 43,227 39,766 ========= ========= ========= ========= Diluted 44,735 39,892 44,151 39,766 ========= ========= ========= ========= Stock-based compensation is included in expenses in the following categories: Sales, marketing and administrative $ 4,844 $ 7,497 $ 18,723 $ 21,956 Research and development 567 621 1,624 1,833 Cost of goods sold 23 - 53 - --------- --------- --------- --------- $ 5,434 $ 8,118 $ 20,400 $ 23,789 ========= ========= ========= ========= NuVasive, Inc. Condensed Consolidated Balance Sheets (in thousands) September 30, December 31, 2012 2011 ------------- ------------- (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 107,731 $ 163,492 Short-term marketable securities 134,899 146,228 Accounts receivable, net 78,140 87,736 Inventory 132,958 119,313 Deferred tax assets, current 54,550 54,550 Prepaid expenses and other current assets 7,264 20,518 ------------- ------------- Total current assets 515,542 591,837 Property and equipment, net 131,158 124,754 Long-term marketable securities 42,416 32,503 Intangible assets, net 105,086 108,140 Goodwill 162,333 159,349 Deferred tax assets 19,857 19,857 Restricted cash and investments 182,067 68,600 Other assets 26,169 18,522 ------------- ------------- Total assets $ 1,184,628 $ 1,123,562 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 63,498 $ 51,744 Accrued payroll and related expenses 22,527 22,215 Litigation liability - 101,200 Acquisition-related liabilities 32,389 32,221 Senior Convertible Notes, current 74,311 - ------------- ------------- Total current liabilities 192,725 207,380 Senior Convertible Notes 329,143 394,019 Deferred tax liabilities 4,180 3,952 Litigation liability 101,200 - Other long-term liabilities 15,581 13,461 Commitments and contingencies Noncontrolling interests 10,033 10,705 Stockholders' equity: Preferred stock - - Common stock 44 42 Additional paid-in capital 705,931 674,790 Accumulated other comprehensive income 1,166 477 Accumulated deficit (175,375) (181,264) ------------- ------------- Total stockholders' equity 531,766 494,045 ------------- ------------- Total liabilities and stockholders' equity $ 1,184,628 $ 1,123,562 ============= ============= NuVasive, Inc. Unaudited Condensed Consolidated Statements of Cash Flows (in thousands) Nine Months Ended September 30, ------------------------ 2012 2011 ----------- ----------- Operating activities: Consolidated net income (loss) $ 5,218 $ (60,675) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 38,237 24,847 Amortization of debt discount 9,435 3,076 Amortization of debt issuance costs 1,386 2,588 Stock-based compensation 20,400 23,789 Allowance for excess and obsolete inventory, net of write-offs 2,000 4,642 Allowance for doubtful accounts and sales return reserve 816 1,261 Accretion of contingent consideration 708 587 Gain recognized on change in fair value of derivatives - (2,387) Deferred income tax expense - 6,238 Other non-cash adjustments 4,294 3,545 Changes in operating assets and liabilities, net of effects of acquisitions: Accounts receivable 8,421 (3,152) Inventory (14,222) (19,933) Prepaid expenses and other current assets 13,582 (1,061) Accounts payable and accrued liabilities 4,474 504 Litigation liability - 101,200 Accrued payroll and related expenses (269) 584 Income taxes payable 5,006 (32,237) ----------- ----------- Net cash provided by operating activities 99,486 53,416 Investing activities: Cash paid for business and asset acquisitions (9,838) (1,100) Purchases of property and equipment (35,706) (39,435) Purchases of marketable securities (192,759) (244,209) Sales of marketable securities 193,035 124,205 Purchases of restricted investments (113,331) (4,535) Payment for specific rights in connection with supply agreement, net of refund received - (5,000) ----------- ----------- Net cash used in investing activities (158,599) (170,074) Financing activities: Proceeds from the sale of warrants - 47,898 Proceeds from the issuance of convertible debt, net of issuance costs - 391,334 Purchase of convertible note hedges - (80,097) Repurchase of 2013 Senior Convertible Notes - (118,702) Proceeds from the issuance of common stock 3,183 4,461 Other assets 132 (349) Tax benefits related to stock-based compensation awards - 638 ----------- ----------- Net cash provided by financing activities 3,315 245,183 Effect of exchange rate changes on cash 37 (179) ----------- ----------- (Decrease) increase in cash and cash equivalents (55,761) 128,346 Cash and cash equivalents at beginning of period 163,492 92,597 ----------- ----------- Cash and cash equivalents at end of period $ 107,731 $ 220,943 =========== ===========


Contact:
Michael J. Lambert
EVP & Chief Financial Officer
NuVasive, Inc.
858-909-3394
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES